Baxter Locks Up European Rights To Onconova’s Late-Stage Cancer Drug Rigosertib
This article was originally published in The Pink Sheet Daily
Executive Summary
For an myelodysplastic syndrome and pancreatic cancer drug, the diversified pharma and device company paid $50 million upfront, plus a generous $515 million in milestones that could pay out before the drug is even commercialized.